DeepMed Research

Osoresnontrine

Generic Name: Osoresnontrine

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₇N_₅O_₂

CAS Number: 1189767-28-9

Unique Ingredient Identifier: O9OC34WOAY

Background: Osoresnontrine is under investigation in clinical trial NCT02281773 (A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.).

Clinical Trials

A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Lamotrigine
Drug: BI 409306
Drug: Placebo
Drug: BI 425809

First Posted Date: 2020-10-26

Last Posted Date: 2024-03-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 40

Registration Number: NCT04602221

Locations: 🇺🇸
Hassman Research Institute, Marlton, New Jersey, United States
🇺🇸
Collaborative Neuroscience Research, LLC, Long Beach, California, United States

This Study in Healthy Men and Women Tests Whether BI 409306 Has an Effect on the ECG (Thorough QT Study)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 409306
Drug: Moxifloxacin
Drug: Placebo matching to BI 409306

First Posted Date: 2019-05-01

Last Posted Date: 2024-03-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 47

Registration Number: NCT03934203

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

This Study in Healthy Men and Women Tests How the Body Takes up BI 409306

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 409306 (C-13/N-15)
Drug: BI 409306

First Posted Date: 2018-04-23

Last Posted Date: 2024-08-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 9

Registration Number: NCT03505151

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months

Phase 2

Terminated

Conditions: Schizophrenia

Interventions: Drug: BI 409306
Drug: Placebo

First Posted Date: 2017-11-22

Last Posted Date: 2025-05-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 264

Registration Number: NCT03351244

Locations: 🇺🇸
Collaborative Neuroscience Network, LLC (CNS), Torrance, California, United States
🇺🇸
Reliable Clinical Research, Hialeah, Florida, United States
🇺🇸
Hassman Research Institute, Berlin, New Jersey, United States

and more 54 locations

This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year

Phase 2

Terminated

Conditions: Psychotic Disorders

Interventions: Drug: Placebo
Drug: BI 409306

First Posted Date: 2017-07-26

Last Posted Date: 2025-05-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 50

Registration Number: NCT03230097

Locations: 🇺🇸
Michigan Clinical Research Institute PC, Ann Arbor, Michigan, United States
🇺🇸
Precise Research Centers, Flowood, Mississippi, United States
🇺🇸
PRIME Clinic, New Haven, Connecticut, United States

and more 30 locations

This Study Tests in Healthy Korean Women Which Effects BI 409306 and a Birth-control Pill Have on Each Other

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Microgynon® 30
Drug: BI 409306

First Posted Date: 2017-06-20

Last Posted Date: 2024-03-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT03193307

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Drug-drug Interaction Trial Between Rifampicin and BI 409306 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 409306
Drug: Rifampicin

First Posted Date: 2017-05-12

Last Posted Date: 2024-03-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT03151499

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Investigation of Pharmacokinetic Drug-drug Interaction of BI 409306 and Donepezil in Healthy Male and Female Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 409306
Drug: Donepezil

First Posted Date: 2015-12-21

Last Posted Date: 2024-08-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT02635750

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

BI 409306 Cardiac Safety Trial in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 409306

First Posted Date: 2015-05-08

Last Posted Date: 2024-10-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT02438683

Locations: 🇩🇪
1289.28.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

Phase 2

Completed

Conditions: Alzheimer Disease

Interventions: Drug: Placebo
Drug: BI 409306
Drug: Donepezil

First Posted Date: 2015-01-14

Last Posted Date: 2018-11-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 329

Registration Number: NCT02337907

Locations: 🇫🇷
HOP La Pitié Salpêtrière, Paris, France
🇩🇪
Praxis Dr. med. Volker Schumann, Berlin, Germany
🇫🇷
HOP Pellegrin, Bordeaux, France

and more 57 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy